Aurobindo Pharma Ltd

NSE: AUROPHARMA · BSE: 524804 · Pharmaceuticals & Biotechnology · 63 announcements

Aurobindo Pharma Ltd news stories on ALFA NewsRead the news →

Share price: ₹1,680.80
Market cap: ₹97,621 Cr
Revenue (annual): ₹33,653 Cr
Net profit (annual): ₹3,505 Cr
P/E (TTM): 24.8×Sector 47.4×
Promoter holding: 51.88%+0.06% QoQ
FII holding: 16.38%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

5 Aug 2026 19:48 IST NSE

Aurobindo Pharma Q1 FY27 Results: Net Profit ₹1,032 Cr, Up 25.2% YoY

Aurobindo Pharma Ltd reported revenue from operations of ₹9,150 Cr (+16.3% YoY) and net profit of ₹1,032 Cr (+25.2% YoY) for Q1 FY27.

Key figure: Net profit ₹1,032 Cr · +25.2% YoY

Open full results → Read the filing ↗

21 May 2026 19:41 IST NSE

Financial Results

Aurobindo Pharma Q4 FY26 Results: Net Profit ₹920.8 Cr, Up 2.0% YoY

Aurobindo Pharma Ltd reported revenue from operations of ₹8,853 Cr (+5.6% YoY) and net profit of ₹920.8 Cr (+2.0% YoY) for Q4 FY26.

Key figure: Net profit ₹920.8 Cr · +2.0% YoY

Open full results → Read the filing ↗

21 May 2026 19:40 IST NSE

Financial Results

Aurobindo Pharma Financial Results

Aurobindo Pharma reported consolidated annual revenue of ₹33,653.08 Crore and profit after tax of ₹3,502.97 Crore. The results show consistent performance across its global pharmaceutical operations.

Value: ₹33,653 Cr

Read the filing ↗